Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 15, 2025Journal of Applied Pharmaceutical ScienceOpen Access

Immunogenicity evaluation of an Alum-adjuvanted recombinant prefusion RBD-Fd SARS-CoV-2 protein subunit produced in Glycoengineered Pichia pastoris

View Full Paper
Ask AI
Bookmark
Share

Authors

AWAndri WardianaHHHariyatun HariyatunDADian Fitria Agustiyanti

Discussion

Loading...

Member takes

Overview

This study evaluates immunogenicity of a recombinant protein vaccine in mice, highlighting its potential as a SARS-CoV-2 alternative.

Key Points

  • The alum-adjuvanted RBD-Fd protein formulation generated a strong antibody response in mice after vaccination.
  • Administration of 5 μg or 10 μg doses led to effective humoral immunity with partial T cell activation.
  • Protein was expressed in glycoengineered Pichia pastoris to enhance human-like glycosylation for better immunogenicity.
  • Results suggest the potential of RBD-based subunit vaccines for addressing SARS-CoV-2 variants.

Cite This Study

Wardiana et al. (2025) studied this question.

synapsesocial.com/papers/68efa18f9d05deea71d13f4chttps://doi.org/10.7324/japs.2026.270912
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preclinical assessment of a recombinant RBD-Fc fusion protein as SARS-CoV-2 candidate vaccine2024 · 10 citations
  2. 2Adjuvant combination and antigen multimerization shape neutralizing antibody and T cell responses to a SARS-CoV-2 RBD subunit vaccine2025
  3. 3Co‐delivery of a trimeric spike DNA and protein vaccine with aluminum hydroxide enhanced Th1‐dominant humoral and cellular immunity against SARS‐CoV‐22023 · 5 citations
  4. 4Recombinant RBD-based subunit vaccines incorporating high-frequency mutation sites elicit cross-immunity and robust protection against SARS-CoV-22026
  5. 5Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-22023 · 28 citations